secwatch.observer — SEC 8-K summary
======================================

Issuer:     AMGEN INC (AMGN)
CIK:        0000318154
Form:       8-K
Filed at:   2025-11-04T23:59:59+00:00
Accession:  0000318154-25-000070
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Amgen Q3 revenue up 12% to $9.6B, GAAP EPS $5.93, non-GAAP EPS $5.64
--------------------------------------------------------------------

- Revenue $9.6B (+12% YoY), product sales growth 12% on 14% volume growth, partially offset by 4% lower net price.
- GAAP EPS $5.93 (+14% YoY), includes $400M Otezla intangible asset impairment charge.
- Non-GAAP EPS $5.64 (+1% YoY); non-GAAP operating margin 47.1%, down 2.5 ppt.
- Free cash flow $4.2B vs $3.3B in Q3 2024, driven by working capital timing and lower interest.
- Sixteen products delivered double-digit sales growth including Repatha, EVENITY, TEZSPIRE, and BLINCYTO.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/318154/000031815425000070/0000318154-25-000070-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/318154/000031815425000070/amgn-20251104.htm
  HTML page:      https://secwatch.observer/filing/0000318154-25-000070

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer